Akcea Therapeutics
Akcea Therapeutics is a development and commercialization company focused on helping patients living with serious cardiometabolic lipid disorders.
The US firm, an affiliate of Ionis Pharmaceuticals, seeks to bring transformative medicines to patients by driving clinical program execution, understanding patient need and commecializing globally.
Akcea has a robust portfolio of development-stage drugs covering multiple targets and diseases using advanced RNA-targeted antisense therapeutics.
Latest Akcea Therapeutics News & Features
26 November 2021
4 November 2020
18 September 2020
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze